



PHARMACOLOGY 2019

15–17 December | Edinburgh

SUBMIT AN ABSTRACT

- Participate in the UK's leading pharmacology event
 - Share your research with over 1,200 attendees
 - Apply for awards and attendance bursaries
 - Have your work published in the British Journal of Pharmacology or the British Journal of Clinical Pharmacology
- 
- 



**SUBMIT
NOW**



Deadline to submit
9 September



BRITISH
PHARMACOLOGICAL
SOCIETY



@BritPharmSoc #Pharmacology2019

Norel Xavier (Orcid ID: 0000-0003-0734-3359)

Bronchodilation induced by PGE₂ is impaired in Group-III pulmonary hypertension

Gulsev Ozen^{2,#}, Chabha Benyahia^{1,3,#}, Salma Mani^{1,3,4}, Kamel Boukais¹, Adam M. Silverstein⁵, Richard Bayles¹, Andrew C. Nelsen⁵, Yves Castier⁶, Claire Danel⁶, Hervé Mal⁶, Lucie H. Clapp⁷, Dan Longrois^{1,3,6} and Xavier Norel^{1,3,*}.

¹INSERM, UMR-S 1148, CHU X. Bichat, Paris, France; ²Istanbul University, Faculty of Pharmacy, Department of Pharmacology, Istanbul 34116, Turkey; ³Paris 13 University, USPC, 93430 Villetaneuse, France; ⁴Institut Supérieur de Biotechnologie de Monastir (ISBM), Université de Monastir - Tunisia; ⁵United Therapeutics, Research Triangle Park, NC 27709, USA; ⁶Hôpital Bichat-Claude Bernard, AP-HP, Paris Diderot University, Université de Paris, 75018 Paris, France; ⁷Institute of Cardiovascular Science, University College London, London WC1E 6JF, UK.

These authors contributed equally to this work.

***Corresponding author** at: INSERM U1148, Hôpital Bichat, 46 rue H. Huchard, 75018 Paris, France. E-mail address: xavier.norel@inserm.fr (X. Norel).

Running title: Loss of PGE₂-induced bronchodilation in pulmonary hypertensive lung

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bph.14854

Abstract

Background and purpose: In patients with pulmonary hypertension (PH) associated with lung disease and/or hypoxia (Group III), a reduction of pulmonary vascular tone and tissue hypoxia are considered therapeutically beneficial. Prostaglandin (PG) E₂ and PGI₂ induce potent relaxation of human bronchi from non-PH (control) patients *via* EP4 and IP receptors, respectively. However, the effects of PGE₂/PGI₂ and their mimetics on human bronchi from PH-patients are unknown. Our aim was to compare the relaxant effects of several PGI₂-mimetics approved for treating PH-Group I with several PGE₂-mimetics in bronchial preparations derived from PH-Group III and control patients.

Experimental approach: Using an organ bath system, the tone of bronchial muscle was investigated in tissue from either control or PH-Group III patients. Expression of prostanoid receptors were analyzed by Western blot and real-time PCR and endogenous PGE₂, PGI₂ and cAMP levels were determined by ELISA.

Key Results: Maximal relaxations induced by different EP4 agonists (PGE₂, L-902688, ONO-AE1-329) were significantly decreased in human bronchi from PH-patients versus controls. In contrast, the maximal relaxations produced by PGI₂-mimetics (iloprost, treprostinil, beraprost) were similar for both groups of patients. Both EP4 and IP receptor protein and mRNA expressions were significantly lower in human bronchi from PH-patients. cAMP levels significantly correlated with PGI₂ but not with PGE₂ levels.

Conclusion and implications: This study shows that PGI₂-mimetics have preserved maximal bronchodilation in PH-Group III patients. The decreased bronchodilation induced by EP4 agonists suggests that restoration of EP4 expression in airways of PH-patients with respiratory diseases could bring additional therapeutic benefit.

Abbreviations: Pulmonary hypertension (PH); chronic obstructive pulmonary disease (COPD); mean pulmonary arterial pressure (mPAP); 6-minute walk distance (6MWD); forced expiratory volume (FEV); forced vital capacity (FVC).

Keywords: human pulmonary hypertension; prostacyclin; prostaglandin E₂; human bronchi relaxation; respiratory diseases; prostanoid receptors.

Bullet point summary:

- ‘What is already known’: Inhaled prostaglandin (PG)-I₂ mimetics are major vasodilators used in the treatment of pulmonary hypertension (PH).
- ‘What this study adds’: Relaxation to PGE₂ but not PGI₂ mimetics, is impaired in isolated bronchi derived from PH-Group III patients.
- ‘Clinical significance’: The impairment of PGE₂-induced bronchodilation via EP4-receptors could be involved in PH-Group III pathogenesis.

Targets

IP receptor

<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=345>

EP4 receptor

<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=343>

EP2 receptor

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=341>

DP1 receptor

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=338>

COX

<https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=269>

TP receptor

<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=346>

DP2 receptor

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=339>

EP2 receptor

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=341>

EP1 receptor

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=340>

EP3 receptor

<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=342>

Ligands

PGI₂

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915>

iloprost

<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1895>

treprostinil

<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5820>

MRE-269

<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5852>

beraprost

<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=summary&ligandId=1967>

PGE₂

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883>

PGD₂

<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881>

histamine

<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1204>

indomethacin

<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1909>

BAY u3405

<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1911>

ONO-AE1-329

<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1933>

L-902688

<https://www.guidetopharmacology.org/GRAC/DatabaseSearchForward?searchString=L-902688+&searchCategories=all&species=none&type=all&comments=includeComments&order=rank&submit=Search+Database>

ONO-AE1-259

<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1932>

CAY10441

<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1969>

GW 627368

<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=summary&ligandId=1953>

ONO-8713

<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1921>

SC-51322

<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1924>

L-816266

<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=summary&ligandId=5844>

DG-041

<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5822>

Declaration of transparency and scientific rigour

Design & Analysis

<https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.14207>

Immunoblotting and Immunochemistry

<https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.14208>

Introduction

Pulmonary hypertension (PH) is, as recently evidenced, defined as mean pulmonary arterial pressure (mPAP) higher than 20 mmHg and is associated with a high rate of mortality (Simonneau *et al.*, 2019). According to classification established by the World Health Organization (Galie *et al.*, 2016), PH Group-III has a high prevalence rate and is associated with chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, emphysema or bronchial dilatation dysfunction (Hoeper *et al.*, 2016). These patients are mostly hypoxic, and the administration of supplemental oxygen is an important standardized step in their treatment (Fein *et al.*, 2016).

Prostaglandin (PG) I₂ (prostacyclin) and mimetics (iloprost, treprostinil, MRE-269, beraprost) are known to be effective treatment options for Group I pulmonary arterial hypertension (PAH) patients, through their vasodilatory and anti-proliferative properties in pulmonary vessels (Clapp & Gurung, 2015; Hill *et al.*, 2015; Pluchart *et al.*, 2017). In addition, some studies with PH Group-III patients demonstrate that PGI₂-mimetics improve 6-minute walk distance (6MWD), dyspnea, and mPAP (Bourge *et al.*, 2013; Hoeper *et al.*, 2016; Olschewski *et al.*, 1999; Shimizu *et al.*, 2011). These studies and others support that vasorelaxant therapy in Group-III patients with severe PH could be beneficial (Harari *et al.*, 2017; Olschewski *et al.*, 1999; Reichenberger *et al.*, 2007).

Respiratory function is one of the key parameters in PH-patients; therefore, agents that induce bronchorelaxation and reduce hypoxia may provide greater benefit for PH Group-III patients (Harari *et al.*, 2017). In addition, if agents are delivered through the inhaled route, like iloprost or treprostinil, then bronchodilation could enhance both drug and oxygen delivery to the pulmonary vessels and blood circulation, while avoiding untoward ventilation/perfusion mismatch potential (Bourge *et al.*, 2013; Pluchart *et al.*, 2017).

The dilatory effects of PGI₂ and mimetics are mostly mediated via stimulation of the IP-receptor in human pulmonary vessels and bronchi (Haye-Legrand *et al.*, 1987; Norel *et al.*, 1999). However, if we consider the other prostanoid receptors involved in relaxation, iloprost can also bind somewhat to EP4 receptors and treprostinil potently can bind to EP2, DP1, and somewhat to EP4 receptors, which are preferential receptors for PGE₂ (EP1-4) and PGD₂ (DP1) (Abramovitz *et al.*, 2000; Whittle *et al.*, 2012). These affinities exhibited by some PGI₂-mimetics for other PG receptors could have beneficial effects since PGE₂, and in particular EP4-agonists, are known to induce bronchorelaxation in humans (Benyahia *et al.*, 2012; Buckley *et al.*, 2011; Safholm *et al.*, 2015). Furthermore, PGE₂, via the EP4-receptor, has been shown to inhibit proliferation and migration of human airway smooth muscle cells and play an

anti-inflammatory role in lungs (Aso *et al.*, 2013; Birrell *et al.*, 2015; Mori *et al.*, 2011). However, these protective effects of EP4-agonists were shown only in healthy subjects, and it is not known whether these functions will be similar in PH Group-III patients.

Clinically, the efficacy of PH treatments is evaluated by decreased dyspnea and improved capacity to perform physical effort (6MWD). In this perspective, bronchial reactivity could also enhance cardio-respiratory performance, most likely in PH Group-III patients. Given the complexity of adaptation to physical effort and exertion, when the above-mentioned prostanoids are investigated in the context of PH, it is important to understand how these agonists differentially affect airway reactivity and which prostanoid receptors are involved. Therefore, the aim of our study was to assess these complex interactions using bronchial preparations derived from control or PH Group-III patients.

Methods

Human pulmonary bronchial preparations

Human bronchial preparations were collected in Bichat Hospital (Paris) after obtaining patients' informed consent with Ethics Committee approval from INSERM and AP-HP (CEERB du GHU Nord) Institutional Review Board (n° IRB00006477). These investigations conform to the principles outlined in the Declaration of Helsinki. Control bronchi preparations were obtained from patients (25 male, 14 female) who underwent surgery mostly for lung carcinoma while PH bronchial preparations were obtained from patients (13 male, 9 female) who had undergone surgery for lung transplantation. Categories of patients are PH due to lung diseases and/or hypoxia [(Group-III of PH classification (Galie *et al.*, 2016)] with detailed characteristics presented in Table S1 and control patient characteristics were presented in Table S2. PH lungs used in our study were from patients having catheter-measured mPAP \geq 20 mmHg. Bronchi were carefully removed from the macroscopically normal regions of the lungs. All preparations were used within 1–12 h post-surgery.

Organ bath and isometric measurements

Human bronchial specimens derived from control and PH-patients (3- to 6-mm internal diameter) were cut as rings and set up in 10 ml organ baths containing Tyrode's solution (concentration mM): NaCl 139.2, KCl 2.7, CaCl₂ 1.8, MgCl₂ 0.49, NaHCO₃ 11.9, NaH₂PO₄ 0.4, glucose 5.5, gassed with 5% CO₂ and 95% O₂ at 37°C and pH 7.4. Each ring was initially stretched to an optimal load (~1-2 grams). Following equilibration (90 min), the preparations were pre-contracted with histamine (50 μ M) in the presence of the cyclooxygenase inhibitor (indomethacin; 1.7 μ M) or TP/DP2 (CRTH2) receptor antagonist (BAY-u3405; 1 μ M, when PGE₂ was used as a relaxant agonist). These agents were used to avoid any physiological effects induced by the release of endogenous prostanoids and/or activation of the thromboxane receptor (TP) by PGE₂. When the response reached a plateau, a cumulative concentration of EP receptor agonists [PGE₂ (EP1-4), ONO-AE1-329 (EP4), L-902688 (EP4), or ONO-AE1-259 (EP2)] or PGI₂-mimetics (iloprost, treprostinil, beraprost, or MRE-269) were added to the baths (1 nM to 10 μ M).

For the pharmacological studies, control preparations were incubated in the presence or absence of one of the following prostanoid receptor antagonists: RO3244019 (AGN-230933) or CAY10441 (IP), GW627368 (EP4/TP), L-877499 (DP1), BAY-u3405 (TP), ONO-8713 or SC-51322 (EP1), L-826266 or DG-041 (EP3). Following the incubation period, a precontraction was induced with histamine (50 μ M) and when the contraction reached a plateau, cumulative concentrations of iloprost and treprostinil were added to the baths.

Measurement of the expression of prostanoid receptors by Western Blot Analysis

The experimental detail provided conforms with British Journal of Pharmacology Guidelines (Alexander *et al.*, 2018). Human bronchial preparations were homogenized under liquid nitrogen using a porcelain mortar. The homogenates were resuspended in RIPA solution containing Tris–HCl buffer (in mM: Tris: 50; NaCl: 150; EDTA: 5; Triton X-100: 1%; sodium desoxycholate 1%; SDS 0.1%) at 4°C (1 ml per 100 mg of tissue) with a protease inhibitor cocktail. The homogenates were centrifuged at 4000 g for 20 minutes, at 4°C. The supernatants were assayed for protein content using a bicinchoninic acid (BCA) protein assay kit. 50 µg of protein were loaded on a 13% sodium dodecyl sulfate (SDS)-polyacrylamide gels. Proteins were transferred to nitrocellulose membranes which were subsequently blocked for 1 h in tris-buffered saline (TBS) 0.1% Tween 20, 5% non-fat dry milk. Membranes were then incubated overnight at 4°C with an anti-EP2 receptor antibody (polyclonal, 1/200), an anti-DP1 receptor antibody (polyclonal 1/200), an anti-EP4 receptor antibody (polyclonal, 1/200) or an anti-IP receptor antibody (polyclonal, 1/500). After overnight incubation, the membranes were washed and then incubated with appropriate peroxidase-conjugated secondary antibody (1/10000). Bands were visualized using the ECL plus luminescence system. For quantification, the *film* was scanned (GS-800 Calibrated densitometer), and the integrated *optical density* of the *bands* was estimated with *Scion Image* software® [RRID:SCR_008673] and normalized to α -actin. The homogenates of rat brain and pulmonary artery smooth muscle cells samples were used as standards for the IP receptor in our Western blot experiments.

Real-Time PCR analysis of prostanoid receptors mRNA expression

Tissue samples (50-100 mg) were placed into a safe lock tubes containing two beads (tungsten carbide beads, 3mm). The preparations were lysed in 1 ml of Qiazol® Lysis Reagent by using the TissueLyser Adapter Set 2 x 24 and ground for 4 min at 30 Hertz. Addition of 300 µL of chloroform followed by a centrifugation (15 min, 16000 g, 4°C), separated the solution with an aqueous phase containing RNA. Total RNA was extracted using the RNeasy Plus Mini kit according to the manufacturer's instructions. The quantity of RNA was measured using a spectrophotometer (NanoDrop 2000c; Thermo Scientific; Waltham, Massachusetts, USA). The preparations were reverse transcribed using Maxima First Strand cDNA Synthesis Kits according to the manufacturer's standard protocol. Real-time PCR were performed in the CFX96 (Bio-Rad CFX Manage; California USA) device with the iQ SYBR Green Supermix Kit, according to the manufacturer's standard protocol, using specific primers (Table S3). To determine the relative accumulation of the prostanoid receptor transcripts in human bronchi

from control or PH-patients, the threshold cycle (CT) values of each transcript were normalized by subtracting the corresponding CT values obtained from the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) control used as the internal standard (ΔCT). The difference in expression of the target genes (EP4-, EP2- and IP- receptors) was analyzed using the formula: $2^{-\Delta\Delta\text{CT}}$, where $\Delta\Delta\text{CT} = (\text{CT}_{\text{prostanoid receptors}} - \text{CT}_{\text{GAPDH}}) - (\text{mean CT}_{\text{prostanoid receptors}} - \text{mean CT}_{\text{GAPDH}})$.

Measurements of cyclic adenosine monophosphate (cAMP), PGI₂ and PGE₂

The endogenous level of cAMP (after acetylation), 6-keto-PGF_{1 α} (a stable metabolite of PGI₂) and PGE₂ were measured in human bronchial homogenate supernatants using an enzyme immunoassay (EIA) kit according to the manufacturer's instructions. The cAMP and prostaglandins concentrations were expressed as pmol/mg or ng/ μg of protein concentrations calculated in these supernatants, respectively. Technical replicates were used to ensure the reliability of single values.

Measurement of functional respiratory tests in patients from the TRIUMPH study

This unpublished data from the pivotal Phase III study of inhaled treprostinil in PH Group-I patients (Benza *et al.*, 2011; McLaughlin *et al.*, 2010) was obtained from United Therapeutics Corporation. The methods used in the TRIUMPH-1 study have been described (Benza *et al.*, 2011; McLaughlin *et al.*, 2010). According to this, eligible patients were between the ages of 18 and 75 years with a confirmed diagnosis of idiopathic or familial PAH or PAH associated with collagen vascular disease, human immunodeficiency virus infection, or anorexigen use. Patients were New York Heart Association (NYHA) functional class III or IV with a baseline 6MWD between 200 and 450 m and were receiving bosentan 125 mg daily or any prescribed dose of sildenafil, 20 mg tid, for at least 3 months before study entry.

Protocol (data on file, courtesy of United Therapeutics, Corp). At Baseline (Visit 1), patients had been assessed to verify that they meet entrance criteria, then underwent a physical exam including a review of PH signs and symptoms and a review of medical history and concomitant medications, chest x-ray, pulmonary function tests (forced expiratory volume, FEV; forced vital capacity, FVC), The Minnesota Living With Heart Failure Questionnaire (MLWHFQ) and vital signs. Patients who had been included in this study provided blood samples and women of childbearing potential (WOCBP) also provided a urine sample for pregnancy testing. Patients had performed a trough (pre-dosing) 6MWD test and had their Borg Dyspnea score noted. Visit 4 had consisted of dosing at the center, measurement of vital signs, and a peak 6MWD with monitoring. Within 24 -72 hours after Visit 4, patients returned (Visit 5) to complete the final study procedures, which included physical examination, including a

review of PH signs and symptoms, vital signs, pulmonary function tests, MLWHF questionnaire, a trough 6MWD, NYHA classification, Borg dyspnea scoring, chest x-ray and provided blood samples.

Data analysis

The data and statistical analysis comply with the recommendations made of the British Journal of Pharmacology on experimental design and analysis in pharmacology (Curtis *et al.*, 2018). For all experiments, the number of observations (group size) is provided in the figure legends, with a minimum of 5 independent observations performed in patient samples. Statistical analysis was undertaken only for studies where each group size was at least $n=5$. The declared group size is the number of independent values, and that statistical analysis was done using these independent values. ELISA measurements were performed in duplicate and an average taken in each sample to calculate the final mean data. The pharmacological protocol was randomly assigned and pre-determined before mounting the bronchial preparations in each organ bath. Experimental blinding was not used for this study as there was one core experimenter responsible for each of the protocols described, where individuals also performed the subsequent analysis. In order to limit experimental bias, analysis was not routinely performed until experimental data set was complete.

Acquisition and processing of the physiological data (contraction/ relaxation) were performed with the IOX software® (EMKA, Paris, France). The effects induced by the different agonists were expressed in grams (g) or normalized (%) with respect to an initial reference contraction (Histamine, 50 μ M) measured just before the addition of the lowest concentration of the vasorelaxant agonist. This allowed for comparison of agonist responses independent of size of bronchial specimens or contraction. The values are positive for contractions and negative for relaxations. Where possible, a four-parameter logistic equation of the form:

$$E = \frac{E_{\max}[A]^{nH}}{EC_{50}^{nH} + [A]^{nH}}$$

was fitted to data obtained from each organ bath protocols to provide estimates of the maximal relaxation (E_{\max}) of the EP or IP receptor ligands [A], the half-maximum effective concentration values (EC_{50}), as well as Hill slope (nH) parameters. All results were analysed using SigmaPlot® [RRID:SCR_003210] for Windows (Systat software, Inc, Richmond, CA, USA 12.0 version). The pEC_{50} values (potency) were calculated as the negative log of EC_{50} values. All data are means \pm s.e.mean (SEM) derived from (n) independent patients and

statistical analysis on the curves, on E_{\max} and pEC_{50} values, on mRNA expression and on the optic density of the band were performed using two or one-way ANOVA followed by Student Newman-Keuls test or Student's *t* test with a confidence level of 95 %. Post hoc tests were carried out only if *F* was significant and there was no variance in homogeneity. Pearson's correlations were performed, correlation coefficient (*r*) were calculated and *P*-values less than 0.05 were considered statistically significant. SigmaStat® [RRID:SCR_010285] statistical software (SYSTAT, Richmond, CA, USA) was used.

Compounds and Materials

Iloprost, beraprost, treprostinil, PGE_2 , MRE-269, BAY-u3405, CAY10441, SC-51322, GW 627368, anti -EP4 [RRID: AB_327850], -EP2 [RRID: AB_327848], -DP1 [RRID: AB_10078133] antibodies and ELISA kits (PGE_2 , 6-keto-PGF $_{1\alpha}$, cAMP) were purchased from Cayman Chemical Company (Ann Arbor, MI, USA). The IP receptor antibody was made as previously described (Falcetti *et al.*, 2010). Treprostinil was also obtained from United Therapeutics Corporation (Silver Spring, MD, USA). ONO-AE1-329, ONO-AE1-259 and ONO-8713 were gifts from Ono Pharmaceutical Co., Ltd. (Chūō-ku, Osaka, Japan); L-902688, L-877499 and L-826266 were gifts from Merck (Kirkland, Quebec, Canada). RO3244019 (AGN-230933) was a gift from Allergan (Irvine, CA, USA); ECL plus luminescence system and nitrocellulose membranes were purchased from Amersham Biosciences (Glattbrugg, Switzerland). Protease inhibitor cocktail, chloroform, indomethacin and primers were purchased from Sigma–Aldrich (St. Louis, MO, USA). RNeasy Plus Mini kit and Qiazol® Lysis Reagent were obtained from Qiagen (Valencia, CA, USA). BCA protein assay kit and Maxima First Strand cDNA Synthesis Kits were purchased from Thermo (Rockford, Illinois, USA). iQ SYBR Green Supermix Kit was from Bio-Rad (Hercules, CA, USA). The peroxidase-conjugated secondary antibody was from Jackson (West Chester, PA, USA). DG-041 was a gift from deCODE Genetics (Reykjavik, Iceland). All compounds were dissolved in ethanol, dimethyl sulfoxide (DMSO) or Tyrode's solution to give a stock solution of 10 mM. Key protein targets and ligands in this article are hyperlinked to corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding *et al.*, 2018), and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander *et al.*, 2017).

Nomenclature of Targets and Ligands

Key protein targets and ligands in this article are hyperlinked to corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS

Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017).

Results

The mean age of the patients was 62 ± 02 (range: 37-81, $n=39$) for control patients, and 54 ± 03 (range: 19-66, $n=22$) for PH-patients. The hemodynamic (clinical) data for control and PH-patients are detailed in Supplementary Methods (Table S1, S2). There is no significant difference in histamine-induced pre-contractions in human bronchial preparations derived from control versus PH-patients [1.54 ± 0.10 g ($n=32$) in control and 1.62 ± 0.14 g ($n=16$) in PH-patients].

Bronchodilation induced by EP2/4-agonists (control vs PH preparations)

PGE₂ and the two EP4 selective agonists (L-902688, ONO-AE1-329) induced potent and concentration-dependent relaxations in pre-contracted human bronchial preparations from control patients. However, these relaxations were significantly decreased in the human bronchial preparations derived from PH-patients (Figure 1A-C). In addition, the potency (pEC₅₀) to PGE₂ was significantly lower in human bronchial preparation from PH-patients versus control patients (Table 1). On the other hand, the selective EP2 agonist ONO-AE1-259 induced no or little relaxation with the highest concentrations (≥ 1 μ M) from control and PH patients (Figure 1D) and no difference was observed between control and PH curves for this agonist (Table 1).

Bronchodilation induced by IP agonists (control vs PH preparations)

IP agonists induced concentration-dependent relaxations in pre-contracted human bronchial preparations. The maximum relaxations induced by iloprost and/or treprostinil were significantly greater versus other IP agonists (beraprost and MRE-269) in either control or PH-patients (Figure 2A-D, Table 2). The pEC₅₀ of iloprost and relaxation induced by iloprost at 1 μ M were significantly lower in human bronchial preparations from PH-patients versus control patients, while there was no difference for the other IP agonists (Figure 2A-D, Table 2). These results comparing relaxation of control bronchial preparations by various PG agonists show that EP4-agonists are 10 to 50-fold more active than IP-agonists (Tables 1-2).

Protein and mRNA levels of prostanoid receptors in human bronchial preparations derived from control and PH-patients.

A significant decrease in both protein and mRNA levels were observed for EP4-receptor and IP-receptor in the human bronchial preparations derived from PH-patients compared to control patients. However, mRNA (preliminary results) and/or protein levels of EP2- or DP1-receptors were not different (Figure 3A-C).

Effects of the prostanoid receptor antagonists on the relaxation induced by IP-receptor agonists

In the presence of IP antagonist (RO3244019, 1 μ M), the relaxations induced by treprostinil and iloprost were completely blocked until 0.1 μ M and partially blocked at 10 μ M in human bronchial preparations from control patients (Figure 4A, B; Table 3). On the other hand, EP4-antagonist (GW627368, 1 μ M and 10 μ M), DP-antagonist (L-877499, 10 μ M), EP1-antagonist (ONO-8713 or SC-51322 10 μ M), EP3-antagonist (L-826266, 3 μ M or DG-041, 1 μ M) or TP-antagonist (BAY-u3405, 1 μ M) did not modify the maximal relaxations induced by iloprost- or treprostinil (Figures 4A-D; Table 3). In contrast, only the pEC₅₀ values calculated for treprostinil were significantly reduced in presence of the EP4- (GW627368, 10 μ M) or DP- (L-877499, 10 μ M) antagonists (Table 3). While the EP1 antagonist did not modify iloprost-induced broncodilations, iloprost induced very small dose-dependent contractions in the presence of IP receptor antagonist (CAY10441, 1 μ M: E_{max}=0.15 \pm 0.04 g, n=5) probably via EP1 activation in our control bronchial preparations at basal tone.

Basal production of cAMP, PGI₂, PGE₂ and correlations

Endogenous levels of PGE₂, PGI₂ (measuring its stable metabolite 6-keto-PGF_{1 α}) and cAMP in bronchial preparations derived from control and PH patients were not significantly different (Table S4). There was a significant positive correlation between PGI₂ and cAMP or PGE₂ levels, while no correlation was found between PGE₂ and cAMP levels (Figure 5).

Results of Pulmonary Function Tests of the patients from the TRIUMPH trial

Lung function testing with 216 μ g/day (nine inhalations four times daily) inhaled treprostinil (Tyvaso®) was performed at baseline and after 12 weeks of treatment in a population of PH Group-I patients (Table 4). There was no evidence of adverse effects of inhaled treprostinil on lung function, as assessed by FVC (median change from baseline 0.0 % in both group) and forced expiratory volume in one second (FEV₁, median change from baseline 0.0% in the active treatment group and -0.5 % in the placebo group).

Discussion

In this current work, we have demonstrated that the maximal relaxations induced by PGE₂ and the two potent, selective EP4-agonists (L-902688, ONO-AE1-329) were strongly and significantly decreased by 35-75% in human bronchial preparations derived from PH Group-III patients compared to controls (Figure 1A-C, Table 1). This decreased reactivity could be explained by the reduced EP4-receptor expression ($\geq 50\%$, mRNA and protein) in PH bronchial preparations (Figure 3A-C). In contrast, the maximal relaxations produced by the PGI₂-mimetics were not modified, even though IP-receptor expression was also reduced in PH bronchial preparations.

Crosstalk between human airways and pulmonary vessels in terms of vascular tone and remodeling has been described for many years (Farah *et al.*, 2009). PH is not only associated with increased pulmonary vascular tone but also with increased respiratory system resistance (Fernandez-Bonetti *et al.*, 1983; Meyer *et al.*, 2002; Schindler *et al.*, 1995). In this context, the efficacy of inhaled PH treatments may be partially related to their direct effect on bronchial tone. Human clinical studies have demonstrated that inhaled PGE₂ exhibited consistent bronchodilation which could be reduced in some pathological conditions (such as asthma) (Kawakami *et al.*, 1973; Melillo *et al.*, 1994; Pavord *et al.*, 1993; Seth *et al.*, 1981; Walters *et al.*, 1982), yet supportive *ex vivo* and *in vitro* studies to further explain these observations are limited.

Although several beneficial effects of PGE₂ or EP4-agonists, such as anti-inflammatory, antiproliferative, and bronchodilatory effects (Aso *et al.*, 2013; Birrell *et al.*, 2015; Mori *et al.*, 2011) have been observed in human airway cells/tissues, their effects in the presence of underlying PH have not been investigated. In the present report we show that EP4-mediated bronchodilation is strongly reduced in PH-patients. This is consistent with observations from a pulmonary model of inflammation, where a downregulation of the EP4-receptor expression has been detected. (Clayton *et al.*, 2005). Inflammation has an important role in the development of PH (Pugliese *et al.*, 2015), and increased inflammatory mediators may be responsible for the decreased EP4-receptor expression that was observed in PH bronchi (Figure 3). Taken together, our results and those of the literature point to the important and complex roles of the EP4-receptor in different lung diseases.

In PH preparations with end stage pathology, among the agents tested in our study, iloprost and treprostinil induced the greater bronchodilations (Figure 2). The reduction in IP- and EP4-receptor expression slightly affects iloprost (IP-/weak EP4- agonist) induced bronchorelaxation and does not affect treprostinil (DP-/EP2-/IP- and weak EP4- agonist)

responses (Abramovitz *et al.*, 2000; Whittle *et al.*, 2012). The relaxation induced by 1 μ M iloprost was significantly decreased (by 33%), as was the pEC₅₀ value, in PH patients (Figure 2A, Table 2). On the other hand, relaxations produced by treprostinil in preparations from PH patients were not different from control and may be explained by a compensatory DP-component (Norel *et al.*, 1999; Whittle *et al.*, 2012).

In control preparations, the bronchodilations induced by iloprost and treprostinil were significantly inhibited by RO3244019, a very selective IP-antagonist (Figure 4A, B; Table 2). These antagonistic effects were surmountable with agonist doses >1 μ M, possibly in a competitive manner or due to some activity of iloprost and treprostinil at EP4- and/or DP-receptors (Abramovitz *et al.*, 2000; Whittle *et al.*, 2012). In particular, using DP- antagonist which significantly decreased the selectivity of treprostinil-induced bronchial (Table 3) or pulmonary vein relaxations (Benyahia *et al.*, 2013). On the other hand, the greater potency of iloprost at the IP-receptor when compared with treprostinil could account for the EP4-antagonist (GW27368) lacking an impact on the iloprost-induced bronchorelaxations in control patients (Figure 4A).

In addition, a significant decrease in IP receptor expression was observed in bronchi derived from PH Group-III patients (Figure 3A-C). Other studies demonstrated similar results either in PASMC derived from PH Group-I patients or in an experimental rat model of PH (Falcetti *et al.*, 2010; Lai *et al.*, 2008). Despite a reduction in IP receptor expression in PH Group-III patients, the ability of PGI₂-mimetics to induce maximal relaxation of *ex vivo* bronchi was not impaired (Figure 2). A similar discrepancy has been demonstrated in PASMC derived from PH Group-I patients, where even in the presence of a strong decrease in IP receptor density, treprostinil was still able to increase cAMP levels (Falcetti *et al.*, 2010). In the current study, the sensitivity (pEC₅₀) and relaxation induced by iloprost at high concentrations were attenuated in bronchi derived from PH Group-III. These results may be explained by the fact that iloprost likely has affinity for both IP- and EP4- receptors at these concentrations, and both receptors are down-regulated in PH patient preparations. Globally, other prostanoid receptors (DP, EP2) and/or peroxisome proliferator-activated receptors, depending of the PGI₂ analogue tested, could account for the maintained bronchorelaxation in PH preparations (Ali *et al.*, 2006; Falcetti *et al.*, 2010; Patel *et al.*, 2018; Turcato & Clapp, 1999).

The different effects of IP and EP4 receptor downregulation on vascular tone may be explained by differences in their signaling pathways and mechanisms of action. For example, cAMP accumulation via G_s activation in vascular smooth muscle cells is thought to be the main

mechanism of IP receptor-induced vasorelaxation, whereas EP4 signaling is not only associated with G_s, but also with G_i (Leduc *et al.*, 2009), phosphatidylinositol 3-kinase (PI3K) (Regan, 2003), β -arrestin (Buchanan *et al.*, 2006; Kim *et al.*, 2010), and β -catenin (Banu *et al.*, 2009; Jang *et al.*, 2012). As shown in Figure 5, cAMP levels were positively correlated with PGI₂ levels but not with PGE₂ levels in homogenates of human bronchial preparations. This suggests that the mechanism of action for IP receptor agonists involving cAMP activation was still functional in PH lungs as shown in hPASMC (Falcetti *et al.*, 2010; Patel *et al.*, 2018), whereas cAMP signaling through EP4 receptor was impaired. The downregulations described here related to PH and/or to the underlying respiratory pathologies could have global implications.

Our *in vitro* results are complemented by *in vivo* data (courtesy of United Therapeutics Corporation) from the TRIUMPH study (Benza *et al.*, 2011), which demonstrated that inhalation of treprostinil does not change respiratory function parameters in patients with PH Group-I. However, in one small prospective study in PH Group-III patients with COPD (Bajwa *et al.*, 2017), the effects of nebulized treprostinil on pulmonary function tests showed a small but statistically significant decrease in FEV1 (median change -0.18 L; P=0.004). Since inhaled treprostinil may cause airway irritation, it is unknown if this change is clinically relevant given the numerical increases in functional improvement. This is in contrast with another study in PH patients (n=7) with pulmonary fibrosis, where no significant changes in pulmonary function tests (FEV, FVC and FEV/FVC ratio) were detected following 12 weeks of parenteral treprostinil monotherapy (Saggar *et al.*, 2014). On the other hand, in these two studies (Benza *et al.*, 2011; Saggar *et al.*, 2014) treprostinil administration improved 6MWD, hemodynamics function or oxygenation in these PH-patients.

The respiratory function data presented from the TRIUMPH study are comparable to data from other studies of nebulized iloprost in PH Group-III patients (Dernaika *et al.*, 2010; Hegewald & Elliott, 2009; Lasota *et al.*, 2013; Olschewski *et al.*, 1999; Reichenberger *et al.*, 2007; Richter *et al.*, 2015). Iloprost treatment demonstrated an absence of effect (or a trend to improvement) on respiratory function and/or oxygenation (Dernaika *et al.*, 2010; Hegewald & Elliott, 2009; Lasota *et al.*, 2013; Reichenberger *et al.*, 2007) and was associated with functional improvement (mPAP, 6MWD in most of the PH Group-III patients with severe PH (mPAP > 35mmHg). However, high doses of PGI₂-analogues could induce airway irritation in some patients (Reichenberger *et al.*, 2007). In terms of dose, one study (Voswinckel *et al.*, 2006) suggests that similar doses of inhaled iloprost (7.5 μ g) or treprostinil (7.5-15 μ g) result in a similar efficiency to reduce pulmonary vascular resistance (PVR) and mPAP in patients

with severe precapillary PH. These data are surprising as iloprost has been always regarded as more potent than treprostinil (Abramovitz *et al.*, 2000; Benyahia *et al.*, 2013; Hiremath *et al.*, 2010; Hoeper *et al.*, 2009; Kumar *et al.*, 2016; Olschewski *et al.*, 2004; Whittle *et al.*, 2012). Yet, our human bronchial preparation data (see Table 2) are supported by the Voswinckel *et al* results, where *in vivo* the same potency was calculated for these PGI₂-analogues, and airways appear to behave differently from vasculature, with potency differences abolished between iloprost and treprostinil.

These clinical studies and our *in vitro* results support that agonists such as iloprost and treprostinil are the most suitable PGI₂-analogues for patients with (severe) PH Group-III. Inhalation of these PGI₂-analogues may be a preferential administration route, where patients could concurrently benefit from airway dilatation, blood oxygenation, and pulmonary vasodilation to reduce hypoxic pulmonary vasoconstriction observed in PH Group-III patients. Our study also reveals the down regulation of IP- EP4-receptor expression levels in the human airways and loss of EP4-agonist-induced relaxation in PH Group-III bronchial preparation, which could be contributing factors for PH Group-III. For this reason, the most potent therapies to activate IP-receptor and those to target the prevention/reversal of EP4 down regulation may be the most effective for treating respiratory dysfunction in these patients.

Acknowledgements: We would like to thank Elisabeth Brunet and Amina El Hilali from the Anapathology laboratory, CHU X. Bichat for their help. The authors would like to thank Erik Borg, (United Therapeutics Corp) for his helpful corrections on the manuscript. We thank Dr. Takayuki Maruyama for providing the ONO compounds. We would like also to thank, Merck, deCODE Genetics and Allergan companies for some compound gifts. Gulsev Ozen is a recipient of a postgraduate fellowship (BIDEB-2214) from the Scientific and Technological Research Council of Turkey (TUBITAK).

Author contributions: Conception and design: XN, GO, CB. Obtaining pulmonary samples and recruitment of patients: YC, HM, CD, DL, XN. Data collection: GO, CB, XN, KB, RB AMS, ACN, SM. Analysis and/or interpretation: XN, GO, CB. Writing of the manuscript for intellectual content: GO, XN, DL, CB. Review of manuscript: DL, AMS, ACN, LHC.

Conflict of interest: This work was funded by an educational research grant from United Therapeutics to XN. LC has received educational research grants from United Therapeutics and honoraria UTC. AMS and ACN are employees of United Therapeutics.

Declaration of transparency and scientific rigour

This Declaration acknowledges that this paper adheres to the principles for transparent reporting and scientific rigour of preclinical research as stated in the BJP guidelines for Design & Analysis, and Immunoblotting and Immunochemistry, and as recommended by funding agencies, publishers and other organisations engaged with supporting research.

References

Abramovitz M, Adam M, Boie Y, Carriere M, Denis D, Godbout C, *et al.* (2000). The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. *Biochim Biophys Acta* 1483: 285-293.

Alexander SP, Christopoulos A, Davenport AP, Kelly E, Marrion NV, Peters JA, *et al.* (2017). THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors. *Br J Pharmacol* 174 Suppl 1: S17-S129.

Alexander SPH, Roberts RE, Broughton BRS, Sobey CG, George CH, Stanford SC, *et al.* (2018). Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of Pharmacology. *Br J Pharmacol* 175: 407-411.

Ali FY, Egan K, FitzGerald GA, Desvergne B, Wahli W, Bishop-Bailey D, *et al.* (2006). Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. *Am J Respir Cell Mol Biol* 34: 242-246.

Aso H, Ito S, Mori A, Suganuma N, Morioka M, Takahara N, *et al.* (2013). Differential regulation of airway smooth muscle cell migration by E-prostanoid receptor subtypes. *Am J Respir Cell Mol Biol* 48: 322-329.

Bajwa AA, Shujaat A, Patel M, Thomas C, Rahaghi F, & Burger CD (2017). The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease. *Pulm Circ* 7: 82-88.

Banu SK, Lee J, Speights VO, Jr., Starzinski-Powitz A, & Arosh JA (2009). Selective inhibition of prostaglandin E2 receptors EP2 and EP4 induces apoptosis of human endometriotic cells through suppression of ERK1/2, AKT, NFkappaB, and beta-catenin pathways and activation of intrinsic apoptotic mechanisms. *Mol Endocrinol* 23: 1291-1305.

Benyahia C, Boukais K, Gomez I, Silverstein A, Clapp L, Fabre A, *et al.* (2013). A comparative study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor. *Prostaglandins Other Lipid Mediat* 107: 48-55.

Benyahia C, Gomez I, Kanyinda L, Boukais K, Danel C, Leseche G, *et al.* (2012). PGE(2) receptor (EP(4)) agonists: potent dilators of human bronchi and future asthma therapy? *Pulm Pharmacol Ther* 25: 115-118.

Benza RL, Seeger W, McLaughlin VV, Channick RN, Voswinckel R, Tapson VF, *et al.* (2011). Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. *J Heart Lung Transplant* 30: 1327-1333.

Birrell MA, Maher SA, Dekkak B, Jones V, Wong S, Brook P, *et al.* (2015). Anti-inflammatory effects of PGE2 in the lung: role of the EP4 receptor subtype. *Thorax* 70: 740-747.

Bourge RC, Tapson VF, Safdar Z, Benza RL, Channick RN, Rosenzweig EB, *et al.* (2013). Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension. *Cardiovasc Ther* 31: 38-44.

Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, & DuBois RN (2006). Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. *Proc Natl Acad Sci U S A* 103: 1492-1497.

Buckley J, Birrell MA, Maher SA, Nials AT, Clarke DL, & Belvisi MG (2011). EP4 receptor as a new target for bronchodilator therapy. *Thorax* 66: 1029-1035.

Clapp LH, & Gurung R (2015). The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors. *Prostaglandins Other Lipid Mediat* 120: 56-71.

Clayton A, Holland E, Pang L, & Knox A (2005). Interleukin-1beta differentially regulates beta2 adrenoceptor and prostaglandin E2-mediated cAMP accumulation and chloride efflux from Calu-3 bronchial epithelial cells. Role of receptor changes, adenylyl cyclase, cyclooxygenase 2, and protein kinase A. *J Biol Chem* 280: 23451-23463.

Curtis MJ, Alexander S, Cirino G, Docherty JR, George CH, Giembycz MA, *et al.* (2018). Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers. *Br J Pharmacol* 175: 987-993.

Dernaika TA, Beavin M, & Kinasewitz GT (2010). Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease. *Respiration* 79: 377-382.

Falcetti E, Hall SM, Phillips PG, Patel J, Morrell NW, Haworth SG, *et al.* (2010). Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. *Am J Respir Crit Care Med* 182: 1161-1170.

Farah OR, Li D, McIntyre BA, Pan J, & Belik J (2009). Airway epithelial-derived factor relaxes pulmonary vascular smooth muscle. *Am J Physiol Lung Cell Mol Physiol* 296: L115-120.

Fein DG, Zaidi AN, & Sulica R (2016). Pulmonary Hypertension Due to Common Respiratory Conditions: Classification, Evaluation and Management Strategies. *J Clin Med* 5.

Fernandez-Bonetti P, Lupi-Herrera E, Martinez-Guerra ML, Barrios R, Seoane M, & Sandoval J (1983). Peripheral airways obstruction in idiopathic pulmonary artery hypertension (primary). *Chest* 83: 732-738.

Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, *et al.* (2016). 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Heart J* 37: 67-119.

Harari S, Elia D, & Humbert M (2017). Pulmonary Hypertension in Parenchymal Lung Diseases: Any Future for New Therapies? *Chest*.

Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S, *et al.* (2018). The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. *Nucleic Acids Res* 46: D1091-D1106.

Haye-Legrand I, Bourdillat B, Labat C, Cerrina J, Norel X, Benveniste J, *et al.* (1987). Relaxation of isolated human pulmonary muscle preparations with prostacyclin (PGI₂) and its analogs. *Prostaglandins* 33: 845-854.

Hegewald MJ, & Elliott CG (2009). Sustained improvement with iloprost in a COPD patient with severe pulmonary hypertension. *Chest* 135: 536-537.

Hill NS, Badesch D, Benza RL, D'Eletto TA, Farber HW, Gomberg-Maitland M, *et al.* (2015). Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration. *Ann Am Thorac Soc* 12: 269-273.

Hiremath J, Thanikachalam S, Parikh K, Shanmugasundaram S, Bangera S, Shapiro L, *et al.* (2010). Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. *J Heart Lung Transplant* 29: 137-149.

Hoeper MM, Gall H, Seyfarth HJ, Halank M, Ghofrani HA, Winkler J, *et al.* (2009). Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. *Eur Respir J* 34: 132-137.

Hoeper MM, McLaughlin VV, Dalaan AM, Satoh T, & Galie N (2016). Treatment of pulmonary hypertension. *Lancet Respir Med* 4: 323-336.

Jang MW, Yun SP, Park JH, Ryu JM, Lee JH, & Han HJ (2012). Cooperation of Epac1/Rap1/Akt and PKA in prostaglandin E(2) -induced proliferation of human umbilical

cord blood derived mesenchymal stem cells: involvement of c-Myc and VEGF expression. *J Cell Physiol* 227: 3756-3767.

Kawakami Y, Uchiyama K, Irie T, & Murao M (1973). Evaluation of aerosols of prostaglandins E1 and E2 as bronchodilators. *Eur J Clin Pharmacol* 6: 127-132.

Kim JJ, Lakshmikanthan V, Frilot N, & Daaka Y (2010). Prostaglandin E2 promotes lung cancer cell migration via EP4-betaArrestin1-c-Src signalsome. *Mol Cancer Res* 8: 569-577.

Kumar P, Thudium E, Laliberte K, Zaccardelli D, & Nelsen A (2016). A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration. *Clin Pharmacokinet* 55: 1495-1505.

Lai YJ, Pullamsetti SS, Dony E, Weissmann N, Butrous G, Banat GA, *et al.* (2008). Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension. *Am J Respir Crit Care Med* 178: 188-196.

Lasota B, Skoczynski S, Mizia-Stec K, & Pierzchala W (2013). The use of iloprost in the treatment of 'out of proportion' pulmonary hypertension in chronic obstructive pulmonary disease. *Int J Clin Pharm* 35: 313-315.

Leduc M, Breton B, Gales C, Le Gouill C, Bouvier M, Chemtob S, *et al.* (2009). Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands. *J Pharmacol Exp Ther* 331: 297-307.

McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, *et al.* (2010). Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. *J Am Coll Cardiol* 55: 1915-1922.

Melillo E, Woolley KL, Manning PJ, Watson RM, & O'Byrne PM (1994). Effect of inhaled PGE2 on exercise-induced bronchoconstriction in asthmatic subjects. *Am J Respir Crit Care Med* 149: 1138-1141.

Meyer FJ, Ewert R, Hoeper MM, Olschewski H, Behr J, Winkler J, *et al.* (2002). Peripheral airway obstruction in primary pulmonary hypertension. *Thorax* 57: 473-476.

Mori A, Ito S, Morioka M, Aso H, Kondo M, Sokabe M, *et al.* (2011). Effects of specific prostanoid EP receptor agonists on cell proliferation and intracellular Ca(2+) concentrations in human airway smooth muscle cells. *Eur J Pharmacol* 659: 72-78.

Norel X, Walch L, Labat C, Gascard JP, Dulmet E, & Brink C (1999). Prostanoid receptors involved in the relaxation of human bronchial preparations. *Br J Pharmacol* 126: 867-872.

Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld-Wollbruck B, Grimminger F, *et al.* (1999). Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. *Am J Respir Crit Care Med* 160: 600-607.

Olschewski H, Rose F, Schermuly R, Ghofrani HA, Enke B, Olschewski A, *et al.* (2004). Prostacyclin and its analogues in the treatment of pulmonary hypertension. *Pharmacol Ther* 102: 139-153.

Patel JA, Shen L, Hall SM, Benyahia C, Norel X, McAnulty RJ, *et al.* (2018). Prostanoid EP(2) Receptors Are Up-Regulated in Human Pulmonary Arterial Hypertension: A Key Anti-Proliferative Target for Treprostinil in Smooth Muscle Cells. *Int J Mol Sci* 19.

Pavord ID, Wong CS, Williams J, & Tattersfield AE (1993). Effect of inhaled prostaglandin E2 on allergen-induced asthma. *Am Rev Respir Dis* 148: 87-90.

Pluchart H, Khouri C, Blaise S, Roustit M, & Cracowski JL (2017). Targeting the Prostacyclin Pathway: Beyond Pulmonary Arterial Hypertension. *Trends Pharmacol Sci* 38: 512-523.

Pugliese SC, Poth JM, Fini MA, Olschewski A, El Kasmi KC, & Stenmark KR (2015). The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes. *Am J Physiol Lung Cell Mol Physiol* 308: L229-252.

Regan JW (2003). EP2 and EP4 prostanoid receptor signaling. *Life Sci* 74: 143-153.

Reichenberger F, Mainwood A, Doughty N, Fineberg A, Morrell NW, & Pepke-Zaba J (2007). Effects of nebulised iloprost on pulmonary function and gas exchange in severe pulmonary hypertension. *Respir Med* 101: 217-222.

Richter MJ, Ghofrani HA, Voswinckel R, Seeger W, Schulz R, Reichenberger F, *et al.* (2015). Acute hemodynamic effects of nebulized iloprost via the I-neb Adaptive Aerosol Delivery system in pulmonary hypertension. *Pulm Circ* 5: 162-170.

Safholm J, Manson ML, Bood J, Delin I, Orre AC, Bergman P, *et al.* (2015). Prostaglandin E2 inhibits mast cell-dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor. *J Allergy Clin Immunol* 136: 1232-1239 e1231.

Saggar R, Khanna D, Vaidya A, Derhovanessian A, Maranian P, Duffy E, *et al.* (2014). Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis. *Thorax* 69: 123-129.

Schindler MB, Bohn DJ, Bryan AC, Cutz E, & Rabinovitch M (1995). Increased respiratory system resistance and bronchial smooth muscle hypertrophy in children with acute postoperative pulmonary hypertension. *Am J Respir Crit Care Med* 152: 1347-1352.

Seth RV, Clarke VS, Lewis RA, & Tattersfield AE (1981). Effect of propranolol on the airway response to prostaglandin E2 in normal man. *Br J Clin Pharmacol* 12: 731-735.

Shimizu M, Imanishi J, Takano T, & Miwa Y (2011). Disproportionate pulmonary hypertension in a patient with early-onset pulmonary emphysema treated with specific drugs for pulmonary arterial hypertension. *Intern Med* 50: 2341-2346.

Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, *et al.* (2019). Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *Eur Respir J* 53.

Turcato S, & Clapp LH (1999). Effects of the adenylyl cyclase inhibitor SQ22536 on iloprost-induced vasorelaxation and cyclic AMP elevation in isolated guinea-pig aorta. *Br J Pharmacol* 126: 845-847.

Voswinckel R, Enke B, Reichenberger F, Kohstall M, Kreckel A, Krick S, *et al.* (2006). Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. *J Am Coll Cardiol* 48: 1672-1681.

Walters EH, Bevan M, & Davies BH (1982). Interactions between response to inhaled prostaglandin E2 and chronic beta-adrenergic agonist treatment. *Thorax* 37: 430-437.

Whittle BJ, Silverstein AM, Mottola DM, & Clapp LH (2012). Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. *Biochem Pharmacol* 84: 68-75.

Figure 1




Figure 1. Relaxation induced by EP agonists in human bronchial preparations derived from control and pulmonary hypertensive (PH) Group-III patients. Cumulative concentration-response curves induced by EP receptor agonists [PGE₂ (EP2/4), ONO-AE1-329 (EP4), L-902688 (EP4), ONO-AE1-259 (EP2)]. All rings were treated (30 min) with indomethacin (COX inhibitor, 1.7 μ M) and BAY-u3405 (TP antagonist, 1 μ M, when PGE₂ concentration-response curve was performed). Responses are expressed as a percentage of pre-contraction induced by histamine (His, 50 μ M). Values are means \pm SEM, (n) indicates the number of patients. *Data significantly different from control patients ($P < 0.05$, Two-Way ANOVA) (See Table 1 for pEC₅₀, E_{max} values and statistics).

Figure 2




Figure 2. Relaxation induced by IP agonists in human bronchial preparations derived from control and pulmonary hypertensive (PH) Group-III patients. Cumulative concentration-response curves induced by IP receptor agonists (iloprost, treprostinil, beraprost and MRE-269). All rings were treated (30 min) with indomethacin (COX inhibitor, 1.7 μ M.) Responses are expressed as a percentage of pre-contraction induced by histamine (His, 50 μ M). Values are means \pm SEM, (n) indicates the number of patients. *Data significantly different from control patients (P<0.05, Two-Way ANOVA). See Table 2 for pEC₅₀, E_{max} values and statistics.

Figure 3




Figure 3. Expression of the prostanoid receptors in human bronchial preparations derived from control and pulmonary hypertensive (PH) Group-III patients. (A) Western blot analysis for prostanoid receptors (EP2, EP4, IP and DP) normalized by α -actin in human bronchial preparations. (B) A representative photograph of Western blot of EP2, EP4, IP, DP receptors and actin. (C) Relative expression of EP2, EP4 and IP mRNA normalized by GAPDH (housekeeping gene) in human bronchial preparations. Values are means \pm SEM, (n) indicates the number of patients. *Data significantly different from control patients ($P \leq 0.05$, Student's t test).

Figure 4




Figure 4. Effect of the prostanoïd receptor antagonists on the relaxations induced by IP agonists in human bronchial preparations derived from control patients. Cumulative concentration-response curves induced by IP receptor agonists (iloprost, treprostinil) were performed after an incubation period (30 min) with or without one of the antagonists. The treatments used are DP antagonist (L-877499, 10 μ M), EP4 antagonist (GW627368, 10 μ M), IP antagonist [(RO3244019 (AGN230933)], 1 μ M), EP1 antagonist (ONO-8713 or SC-51322, 10 μ M), EP3 antagonist (L-826266, 3 μ M or DG-041, 1 μ M), TP antagonist (BAY-u3405, 1 μ M). Responses are expressed as a percentage of pre-contraction induced by histamine (His, 50 μ M). Values are means \pm SEM, (n) indicates the number of patients. *Data significantly different from control ($P < 0.05$, Two-Way ANOVA). See Table 3 for pEC_{50} , E_{max} values and statistics.

Figure 5




Figure 5. The correlations between the endogenous levels of PGE₂ and PGI₂ (measuring its stable metabolite 6-keto-PGF_{1α}) or cAMP in homogenates of human bronchial preparations are presented. Coefficient of determination have been calculated (r^2) and $P < 0.05$ indicates significant correlations (Pearson analysis). Data derived from control and pulmonary hypertension Group-III patients, respective n values are presented in parenthesis.

Figure 6

	EP agonists		IP agonists	
Agonists	PGE ₂	ONO-AE1-329 L-902688	iloprost	treprostinil
	↓	↓	↓	↓
Receptor expressions	EP1 EP2 EP3 EP4	EP4	IP PPARs?	IP EP4 DP PPARs?
Effects on bronchodilation of PH preparations	decrease	decrease	decrease (slightly)	no effect

Figure 6. Proposed mechanisms of bronchorelaxation induced by IP and EP receptor agonists in PH Group-III patients. PPAR: peroxisome proliferator activated receptor. Downward arrows indicate decreased expression of prostanoid receptors.

Table 1. Relaxation induced by EP agonists in human bronchial preparations derived from control or pulmonary hypertensive (PH) Group-III patients

	Control patients			PH patients		
	E_{\max} (%)	pEC_{50}	n	E_{\max} (%)	pEC_{50}	n
PGE₂	-105±07	7.03±0.12	8	-69±19*	6.21±0.19*	6
ONO-AE1-329 (EP4)	-79±09	7.07 ±0.11	6	-19±03*	NC	9
L-902688 (EP4)	-63±10	8.04±0.22	9	-20±08*	NC	8
ONO-AE1-259 (EP2)	-19±12	NC	5	-16±06	NC	6

Human bronchial preparations were pre-contracted with histamine (50 μ M) [Control: 1.56±0.17 g; PH: 1.89±0.16 g]. The rings were incubated for 30 min with indomethacin (1.7 μ M) and BAY u3405 (1 μ M, when PGE₂ concentration-response curve was performed). The maximal relaxations (E_{\max}) and the pEC_{50} values are presented. NC: not calculable. The selectivity of receptor agonists is indicated in parentheses. Values represent means±SEM and are derived from cumulative concentration-response curves induced by EP receptor agonists and from (n) different patients. *Data significantly different ($P<0.05$) from respective control values (One-Way ANOVA or Student's t test).

Table 2. Relaxation induced by IP agonists in human bronchial preparations derived from control or pulmonary hypertensive (PH) Group-III patients

	Control patients			PH patients		
	E_{\max} (%)	pEC_{50}	n	E_{\max} (%)	pEC_{50}	n
Iloprost	-94±06 ^{a,b}	6.24±0.13	21	-94±19 ^b	5.68±0.15*	6
Treprostinil	-87±08 ^b	6.15±0.10	25	-93±21 ^b	6.02±0.05	7
Beraprost	-61±08 ^b	6.31±0.18	6	-40±17	5.91±0.21	6
MRE-269	-26±07 ^a	NC	6	-24±06	NC	5

Human bronchial preparations were pre-contracted with histamine (50 μ M) [Control: 1.41±0.12°g; PH: 1.44±0.17 g]. The rings were incubated for 30 min with indomethacin (1.7 μ M). The maximal relaxations (E_{\max}) and the pEC_{50} values are presented. NC: not calculable.

Values represent means±SEM and are derived from cumulative concentration-response curves induced by IP receptor agonists and from (n) different patients. * indicates pEC_{50} values significantly different versus respective control values. In each group of patients ^a or ^b indicates E_{\max} values significantly different versus beraprost or MRE-269, respectively (P<0.05, One-Way ANOVA or Student's t test).

Table 3. Effect of prostanoid receptor antagonists on the relaxation induced by iloprost and treprostinil in human bronchial preparations derived from control patients

IP agonists	Antagonists	E _{max} (%)	pEC ₅₀	n
Iloprost	Control	-94±06	6.24±0.13	21
	RO3244019 (IP, 1 µM)	-87±10	5.65±0.14*	5
	GW627368 (EP4)			
	1 µM	-103±08	5.97±0.28	5
	10 µM	-83±10	6.33±0.22	5
	L-877499 (DP, 10 µM)	-97±13	6.38±0.12	5
	ONO-8713 (EP1, 10 µM)	-84±10	6.25±0.20	5
	L-826266 (EP3, 3 µM)	-93±13	6.37±0.12	5
	BAY-u3405 (TP, 1 µM)	-91±10	6.11±0.24	5
Treprostinil	Control	-87±08	6.15±0.10	25
	RO3244019 (IP, 1 µM)	-44±20*	NC	6
	GW627368 (EP4, 10 µM)	-97±13	5.65±0.14*	6
	L-877499 (DP, 10 µM)	-112±18	5.49±0.23*	5
	SC-51322 (EP1, 10 µM)	-92±23	6.18±0.21	5
	DG-041 (EP3, 1 µM)	-89±12	5.82±0.23	5
	BAY-u3405 (TP, 1 µM)	-122±13	6.07±0.21	6

Human bronchial preparations were pre-contracted with histamine (50 µM). The rings were incubated for 30 min with indomethacin (1.7 µM). The maximal relaxations (E_{max}) and the pEC₅₀ values are presented. NC: not calculable. The selectivity of receptor agonists or antagonists are indicated in parentheses. Values represent means±SEM and are derived from cumulative concentration-response curves induced by IP receptor agonists (iloprost, treprostinil) and from (n) different patients. *Data significantly different (P<0.05) from respective control values (One-Way ANOVA or Student's t test).

Table 4. TRIUMPH study / Respiratory baseline characteristic (Active versus Placebo) for PH Group-I patients receiving treprostinil by inhalation

Statistic	Placebo	Active	P-Value(1)
Total number of patients			
n	120	115	
Force vital capacity (FVC) at baseline force			
n	120	115	0.461 NP
Median	82	83	
Min, Max)	(0.0, 123)	(20.0, 139)	
FVC at week12			
n	109	103	0.741 NP
Median	82	82	
(Min, Max)	(0.0, 127)	(0.0, 149)	
FVC change from baseline to week12			
n	109	103	0.925 NP
Median	0.0	0.0	
(Min, Max)	(-87, 98)	(-99, 23)	
Force expiratory volume (FEV) at baseline			
n	120	115	0.201 NP
Median	74.5	76.0	
(Min, Max)	(0.0, 122)	(19.0, 130)	
FEV at week12			
n	109	103	0.334 NP
Median	73	74	
(Min, Max)	(0.0, 113)	(0.0, 129)	
FEV change from baseline to week12			
n	109	103	0.917 NP
Median	-1.0	0.0	
(Min, Max)	(-78, 77)	(-86, 23)	

(1) Active versus Placebo; NP=non-parametric test; FEV: Forced expiratory volume; FVC:

Force vital capacity.